Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements is a phase 1/2, randomised interventional study registered as NCT05987644 by Joshua Palmer, with a registry enrolment figure of 56 participants, started 2024-03-07 and due to reach its primary completion in 2028-02-28. Interventions recorded: Alectinib; Stereotactic Radiosurgery. Conditions listed: Lung Cancer; NSCLC; Brain Metastases. Primary outcome: Phase 2: Neurological status and control of CNS disease at 12 months compared to alectinib plus SRS in patients with ≤15 CNS metastases; Phase 1b: Safety and Feasibility. Lung eligibility wording from the registry: "Histological or cytological confirmation of Stage IV (per AJCC 8th edition) non-small cell lung cancer (NSCLC)". Sites: United States. No results are recorded here; the registry entry is the source.